BioTuesdays

Category - Markets

soliton

Roth starts Soliton at buy; PT $14

Roth Capital Partners launched coverage of Soliton (NASDAQ:SOLY) with a “buy” rating and $14 price target. The stock closed at $8.80 on March 26. Soliton is an aesthetic company that utilizes acoustic pulse technology...

Cipher Pharmaceuticals

Mackie cuts Cipher Pharma PT to $1 from $2.30

Mackie Research lowered its price target for Cipher Pharmaceuticals (TSX:CPH) to $1 (Canadian) from $2.30, citing a delay in the out-licensing of its Canadian assets because of a dispute with Bausch Health (NYSE:BHC)...

atyr Pharma

HCW cuts aTyr Pharma to neutral and removes PT

H.C. Wainwright downgraded aTyr Pharma (NASDAQ:LIFE) to “neutral” from “buy” and removed its price target, citing delays in topline results from a Phase 1b/2a trial of ATYR1923 for the treatment of sarcoidosis, an...

Eyenovia

Ladenburg cuts Eyenovia PT to $19 from $30

Ladenburg Thalmann lowered its price target for Eyenovia (NASDAQ:EYEN) to $19 from $30, but reiterated its “buy” rating, reflecting dilution associated with a recent financing and anticipated additional dilution...

T2 Biosystems

AGP cuts T2 Biosystems PT to $1.10 from $1.80

Alliance Global Partners lowered its price target for T2 Biosystems (NASDAQ:TTOO) to $1.10 from $1.80 after the company released lower than expected first quarter results but added a COVID-19 program to its platform...

OpGen

AGP ups OpGen PT to $5 from $2.50

Alliance Global Partners raised its price target for OpGen (NASDAQ:OPGN) to $5 from $2.50 after the company reported better than expected fourth quarter results. The stock closed at $2.99 on March 24. OpGen also...

Novavax

Ladenburg ups Novavax PT to $24 from $16

Ladenburg Thalmann raised its price target for Novavax (NASDAQ:NVAX) to $24 from $16 after the company reported impressive pivotal results with its lead asset, NanoFlu. The stock closed at $12.77 on March 24. Analyst...

Molecular Templates

Stifel starts Molecular Templates at buy; PT $19

Stifel initiated coverage of Molecular Templates (NASDAQ:MTEM) with a “buy” rating and $19 price target. The stock closed at $13.29 on March 24. “We believe the engineered toxin body technology from which Molecular’s...